WARRINGTON, Pa., June 7, 2007 (PRIME NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced the initiation of a Phase 2 clinical trial evaluating the use of Surfaxin(r) (lucinactant) in children up to two years of age suffering from Acute Respiratory Failure (ARF). Surfactant dysfunction is a key component of ARF. This new trial will explore the expanded application of surfactant therapy to pediatric critical care medicine. Surfaxin, the first peptide-containing (KL-4) synthetic surfactant, has received an Approvable Letter from the FDA for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. In addition, a reduction in morbidity was observed with Surfaxin in a Phase 2 clinical trial for premature infants at risk for Bronchopulmonary Dysplasia (BPD).
